The tyrosine kinase inhibitor ponatinib and monoclonal antibody blinatumomab — which targets CD19 on leukaemia cells — are highly effective as monotherapies for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL).
The combination may provide an alternative to chemotherapy and stem cell transplant (SCT) without the associated risks and side effects.
In a Phase II trial presented by Nicholas Short, M.D., researchers evaluated the safety and efficacy of the chemotherapy-free combination of ponatinib plus blinatumomab in 55 patients with either newly diagnosed (ND) or relapsed/refractory (R/R) Ph+ ALL and patients with chronic myeloid leukaemia in lymphoid blast phase (CML-LBP).
Complete molecular response was seen in 96% of ND patients, 92% of R/R patients and 83% of CML-LBP patients.
For ND patients, the two-year event-free survival (EFS) rate and overall survival (OS) rate each were 93%. No relapses have been observed, and SCT was not needed in first remission.
The treatment was well-tolerated, suggesting this combination is safe and effective for patients with Ph+ ALL. The promising outcomes in ND patients with Ph+ ALL suggest that this regimen may be able to eliminate the need for chemotherapy and SCT for these patients.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.